Table 1: FDA approved EGF receptor inhibitors.

Generic, brand nameTypeMechanismClinical Dose Range (route)Approved TumorsCompany

Gefitinib, IressaZD1839Small molecule TKIInhibits intracellular EGFR tyrosine kinase phosphorylation250 mg daily (oral)Platinum and taxane resistant nonsmall cell lung cancerAstra-Zeneca

Erlotinib, TarcevaOS-774CP-358774Small molecule TKIInhibits intracellular EGFR tyrosine kinase phosphorylation100 mg–150 mg daily (oral)Nonsmall cell lung cancer, pancreatic cancerOSI Pharmaceuticals/Genentech

Lapatinib, TYKERBGW 572016Small molecule dual TKI, EGFR-1 and EGFR-2,Inhibits heterodimerization and her1/her2 phosphorylation1250 mg daily days 1–21 (oral)Her2 + breast cancer refractory to herceptin and chemoGlaxo-Smith Kline

Cetuximab, ErbituxIMC-C225Human/mouse chimeric MAbExtracellular domain binding and ligand blockade400  m g / m 2 load then 250  m g / m 2 weekly (IV)Metastatic colorectal cancer, head, and neckImClone

Panitumamab, VectibixABX-EGFHumanized MAbExtracellular domain binding and ligand blockade6 mg/kg every 14 days (IV)Metastatic refractory colorectal cancerAmgen/Abgenix